重视药物性肝损伤的临床研究*

doi:10.3969/j.issn.1672-5069.2014.06.001

Abstract

Mao Yimin. Drug-induced liver injury:diagnosis,management and the challenge[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2014, 17(6): 561-564.

[1] Kaplowitz N. Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov,2005,4:489-499.
[2] Russmann S,Jetter A,Kullak-Ublick GA. Pharmacogenetics of drug-induced liver injury. Hepatology,2010,52（2）:748-761.
[3] van Swelm RP1,Laarakkers CM,van der Kuur EC,et al. Identification of novel translational urinary biomarkers for acetaminophen-induced acute liver injury using proteomic profiling in mice. PLoS One,2012,7（11）:e49524.
[4] Imaeda AB,Watanabe A,Sohail MA,et al. Acetaminopheninduced hepatotoxicity in mice is dependent on Tlr9 and the Nalp3inflammasome. J Clin Invest,2009,119:305-314.
[5] Jones DP,Lemasters JJ,Han D,et al. Mechanisms of pathogenesis in drug hepatotoxicity putting the stress on mitochondria. Mol Interv,2010,10（2）:98-111.
[6] Starkey Lewis PJ,Dear J,Platt Vet, et al. Circulating microRNAs as potential markers of human drug-induced liver injury. Hepatology,2011,54（5）,1767-1776.
[7] Starckx S,Batheja A,Verheyen GR,et al. Evaluation of miR-122 and other biomarkers in distinct acute liver injury in rats. Toxicol Pathol,2012,doi:10.1177/0192623312464436.
[8] Daly AK,Day CP. Genetic factors in the pathogenesis of drug-induced liver injury. In:Kaplowitz N,Deleve LD. Drug-induced liver disease,3rd ed. San Diego: Academic Press,2013:215-225.
[9] Lucena M,Molokhia M,Shen Y,et al. Susceptibility to amoxicillin-clavulanateinduced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology,2011,141:338-347.
[10] Daly AK,Donaldson PT,Bhatnagar P,et al. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet,2009,41（7）:816-819.
[11] 茅益民. 药物性肝损伤的临床诊断思路和评估.中华肝脏病杂志,2012,20（3）：167-169.
[12] Chalasani NP,Hayashi PH,Bonkovsky HL,et al. ACG Clinical Guideline:the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol,2014,109（7）: 950-966.
[13] Rochon J,Protiva P,Seeff LB,et al. Reliability of the RUCAM for assessing causality in drug-induced liver injury. Hepatology,2008,48:1175-1183.
[14] Lewis JH. Causality assessment:Which is best—Expert opinion or RUCAM. Clin Liver Dis,2014,4（1）:4-8.
[15] Hoofnagle JH,Serrano J,Knoben JE,et al. LiverTox:a website on drug-induced liver injury. Hepatology,2013,57（3）:873-874.

Drug-induced liver injury:diagnosis,management and the challenge

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Chen Shuai, Yang Changqing.. Pathogenesis and risk factors of portal vein thrombosis [J]. Journal of Practical Hepatology, 2019, 22(6): 761-764.
[2]	Liang Jubo, Miao Qi, Ma Xiong.. Diagnosis and treatment of cholangiocytic cholestasis [J]. Journal of Practical Hepatology, 2019, 22(6): 941-943.
[3]	Liu Liwei, Zhao Xinyan. Clinicopathological features of drug-induced liver injury [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 160-163.
[4]	Huang Chunyang, Shan Jing, Liao Huiyu, Huang Yunli, Han Ying, Zhang Xiaodan, Du Xiaofei, Ren Meixin, Bian Xinqu, Liu Yanmin. Clinical and laboratory characteristics of patients with drug-induced liver injury receiving glucocorticoid therapy [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 208-211.
[5]	Wu Xiuxin, Zhang Huiyong, Zhang Kai. Changes of plasma microRNA-4284 in patients with anti-tuberculosis drug-induced hepatotoxicity [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 212-215.
[6]	Hu Hulan, Zhu Mengfei, Shi Junping.. Non-alcoholic fatty liver disease with concurrent chronic hepatitis B: What’s the progress [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 149-152.
[7]	Sun Wenjing, Chen Dongfeng.. Literature analysis about RUCAM scale and Maria scale in diagnosis of Chinese patients with drug-induced liver injury [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 881-884.
[8]	Cui Ruibing, Yan Ming.. Etiology of ascites:what’s going on [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(5): 657-660.
[9]	Li Yue, Ding Huiguo.. Current diagnosis and treatment of chylous ascites [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(5): 665-668.
[10]	Tong Xin, Fan Hua. Efficacy of bicyclic alcohol on liver function in gastric cancer patients with chemotherapy-induced liver injury [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(4): 625-626.
[11]	Liu Cong, Wang Tingting, Zuo Lili, et al. Analysis of patients with drug-induced liver injury in recent 3 years [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(4): 639-640.
[12]	Liu Liangyi, Su Dongyuan. Comparison of clinical and liver pathological features of patients with drug-induced liver injury and autoimmune hepatitis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(3): 463-464.
[13]	Zeng Minde. Mechanisms of lipotoxicity in pathogenesis of nonalcoholic fatty liver diseases [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(2): 153-156.
[14]	Chi Zhaochun. Pathogenesis of nonalcoholic steatohepatitis and cirrhosis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(2): 166-169.
[15]	Xin Fengzhi, Cao Haixia, Fan Jiangao. Glucagon-like peptide-1 in melioration of non-alcoholic fatty liver disease [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(2): 313-316.